Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.

Ann-Kathrin OehusStephanie G C KroezeNina-Sophie Schmidt-HegemannMarco M E VogelSimon KirsteJessica BeckerIrene A BurgerThorsten DerlinPeter BartensteinMatthias EiberMichael MixChristian la FougèreClaus BelkaStephanie E CombsAnca-Ligia GrosuArndt-Christian MüllerMatthias GuckenbergerHans ChristiansenChristoph Henkenberens

Published in: BMC cancer (2020)

RT as MDT based on PSMA - PET of all metastases of recurrent prostate cancer after RP and sRT represents a viable treatment option for well-informed and well-selected patients.

Keyphrases

prostate cancer
radical prostatectomy
pet ct
pet imaging
early stage
end stage renal disease
computed tomography
positron emission tomography
ejection fraction
newly diagnosed
locally advanced
radiation therapy
peritoneal dialysis
patient reported